[go: up one dir, main page]

NO20002963D0 - Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikament for behandling av svekket glukosetoleranse - Google Patents

Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikament for behandling av svekket glukosetoleranse

Info

Publication number
NO20002963D0
NO20002963D0 NO20002963A NO20002963A NO20002963D0 NO 20002963 D0 NO20002963 D0 NO 20002963D0 NO 20002963 A NO20002963 A NO 20002963A NO 20002963 A NO20002963 A NO 20002963A NO 20002963 D0 NO20002963 D0 NO 20002963D0
Authority
NO
Norway
Prior art keywords
glucose tolerance
impaired glucose
ethylpyridin
pioglitazone
thiazolidine
Prior art date
Application number
NO20002963A
Other languages
English (en)
Other versions
NO314748B1 (no
NO2963A (no
Inventor
Jerrold M Olefsky
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08293899 external-priority patent/US5478852C1/en
Publication of NO2963A publication Critical patent/NO2963A/no
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20002963D0 publication Critical patent/NO20002963D0/no
Publication of NO314748B1 publication Critical patent/NO314748B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20002963A 1993-09-15 2000-06-09 Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikamentfor behandling av svekket glukosetoleranse NO314748B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08293899 US5478852C1 (en) 1993-09-15 1994-08-23 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
PCT/US1994/010389 WO1995007694A1 (en) 1993-09-15 1994-09-14 Use of thiazolidinediones to prevent or delay onset of niddm

Publications (3)

Publication Number Publication Date
NO2963A NO2963A (no) 1996-05-14
NO20002963D0 true NO20002963D0 (no) 2000-06-09
NO314748B1 NO314748B1 (no) 2003-05-19

Family

ID=26820333

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19961041A NO310097B1 (no) 1993-09-15 1996-03-14 Anvendelse av tiazolidindioner for fremstilling av et medikament for å forhindre eller forsinke starten av NIDDM
NO20002964A NO314747B1 (no) 1993-09-15 2000-06-09 Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse
NO20002963A NO314748B1 (no) 1993-09-15 2000-06-09 Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikamentfor behandling av svekket glukosetoleranse

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO19961041A NO310097B1 (no) 1993-09-15 1996-03-14 Anvendelse av tiazolidindioner for fremstilling av et medikament for å forhindre eller forsinke starten av NIDDM
NO20002964A NO314747B1 (no) 1993-09-15 2000-06-09 Anvendelse av tiazolidinonderivater for fremstilling av et medikament for behandling av svekket glukosetoleranse

Country Status (15)

Country Link
EP (2) EP0719140B1 (no)
JP (3) JP3081245B2 (no)
CN (3) CN1103590C (no)
AT (1) ATE376829T1 (no)
AU (3) AU679572B2 (no)
CA (1) CA2171827C (no)
CZ (1) CZ283339B6 (no)
DK (1) DK0719140T3 (no)
ES (1) ES2296288T3 (no)
FI (1) FI961213A7 (no)
HU (1) HU228260B1 (no)
NO (3) NO310097B1 (no)
NZ (1) NZ274346A (no)
RU (1) RU2195282C2 (no)
WO (1) WO1995007694A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ATE399545T1 (de) * 1996-11-08 2008-07-15 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
US6531461B1 (en) * 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
WO2004067001A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
RU2359671C2 (ru) * 2003-01-29 2009-06-27 Такеда Фармасьютикал Компани Лимитед Способ получения препарата с покрытием
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
JP4776537B2 (ja) * 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
FR2858321B1 (fr) * 2003-07-28 2006-01-20 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
MX356584B (es) * 2006-03-16 2018-06-05 Metabolic Solutions Dev Co Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
DK0591252T3 (da) * 1991-06-25 1996-09-30 Pfizer Thiazolidindionhypoglykæmiske midler
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
CN1387849A (zh) 2003-01-01
JPH09502727A (ja) 1997-03-18
HK1011925A1 (en) 1999-07-23
CZ283339B6 (cs) 1998-03-18
CZ79396A3 (en) 1996-10-16
NO961041D0 (no) 1996-03-14
WO1995007694A1 (en) 1995-03-23
NO314748B1 (no) 2003-05-19
NZ274346A (en) 1997-06-24
CA2171827C (en) 2004-06-29
CN1387848A (zh) 2003-01-01
HUT75874A (en) 1997-05-28
NO961041L (no) 1996-05-14
JP3081245B2 (ja) 2000-08-28
CA2171827A1 (en) 1995-03-23
HU228260B1 (en) 2013-02-28
NO20002964D0 (no) 2000-06-09
HU9600653D0 (en) 1996-05-28
NO310097B1 (no) 2001-05-21
AU679572B2 (en) 1997-07-03
FI961213L (fi) 1996-05-14
AU706947B2 (en) 1999-07-01
DK0719140T3 (da) 2008-03-03
CN1202823C (zh) 2005-05-25
EP0719140B1 (en) 2007-10-31
NO2963A (no) 1996-05-14
NO2964A (no) 1996-05-14
ES2296288T3 (es) 2008-04-16
EP0719140A4 (en) 2001-08-16
AU7835194A (en) 1995-04-03
EP1714652A2 (en) 2006-10-25
CN1103590C (zh) 2003-03-26
NO314747B1 (no) 2003-05-19
JP2000273043A (ja) 2000-10-03
JP2000239167A (ja) 2000-09-05
AU1770997A (en) 1997-05-29
CN1202821C (zh) 2005-05-25
EP1714652A3 (en) 2007-01-17
CN1134669A (zh) 1996-10-30
EP0719140A1 (en) 1996-07-03
RU2195282C2 (ru) 2002-12-27
ATE376829T1 (de) 2007-11-15
AU1771097A (en) 1997-05-29
FI961213A7 (fi) 1996-05-14
FI961213A0 (fi) 1996-03-15

Similar Documents

Publication Publication Date Title
NO2963A (no) Anvendelse av forbindelsen 5-[4-[2-(5-etylpyridin-2-yl)- etoksy]benzyl]tiazolidin-2,4-dion (pioglitazone) for fremstilling av et medikament for behandling av svekket glukosetoleranse
NZ501260A (en) Treatment of diabetes with thiazolidinedione and metformin
WO1995007697A3 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
HU9203837D0 (en) Method for producing oxa-dione and thiazolidin-dione compounds reducing sugar and cholesterol levels of blood
PL348773A1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
RU2001131722A (ru) 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]-тиазолидин-2,4 -ди он гидрохлорид, обладающий гипогликемической активностью
NZ504703A (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
CO4940420A1 (es) Nuevo metodo de tratamiento
NO995549L (no) Anvendelse av 5-(4-(2-(M-metyl-N-(2-pyridyl)amino)-etoksy)bensyl)2,4-tiazolidindion ved behandling av polycystisk ovairiesyndrom og gestationell diabetes
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
CO4940489A1 (es) Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos
NZ501256A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
AU539921B2 (en) Thiazolidinedione derivatives
DK0593348T3 (da) Thiazolidin-2,4-dion-derivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende dem
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
NO20030531L (no) Tartratsalter av tiazolidindionderivater
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
NZ522730A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
MK1K Patent expired